Sreedhar Chava, MD
Family Medicine · El Monte, CANPI 1255515383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Merck at 27.9% of the total.
Across 111 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$634
- Sanofi Pasteur Inc.$229
- Amgen$137
- GSK$125
- Novo Nordisk$115
- Pfizer$105
- plus $928 from 21 others
Across 25 payments — averaging $51,422 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$777K
- Roche Diagnostics Operations, Inc.$497K
- GSK$11K
What the payments were for
- Food & beverage$2,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 28 | $634 |
| Sanofi Pasteur Inc. | 12 | $229 |
| Amgen | 7 | $137 |
| GSK | 6 | $125 |
| Novo Nordisk | 5 | $115 |
| Pfizer | 5 | $105 |
| Cranial Technologies, Inc | 5 | $102 |
| Shield Therapeutics Inc | 5 | $95 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| AstraZeneca | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Lilly USA, LLC | 2 | $57 |
| Agile Therapeutics, Inc. | 3 | $57 |
| AbbVie(2 entities) | 3 | $55 |
| Ultragenyx Pharmaceutical Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $41 |
| Boehringer Ingelheim | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Novartis | 1 | $25 |
| Dermira, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $22 |
| Roche Diagnostics Corporation | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Organon | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $12 |
How this compares
$2,272 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 74 | $48,260 |
| OzempicSemaglutide | 28 | $25,623 |
| JanuviaSitagliptin Phosphate | 28 | $18,650 |
| Diclofenac Sodium | 62 | $10,454 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,001 |
| TradjentaLinagliptin | 11 | $5,433 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $4,568 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,071 |
| Celecoxib | 114 | $3,049 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,041 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $2,830 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,559 |
| Atorvastatin Calcium | 269 | $1,871 |
| Gabapentin | 203 | $1,802 |
| Candesartan Cilexetil | 12 | $1,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $36 | $53,69285 claims |
| Novo NordiskOzempic | $115 | $25,62328 claims |
| MerckJanuvia | $634 | $18,65028 claims |
| GSKBreo Ellipta, Shingrix | $125 | $9,56032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in El Monte
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.